To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Jan 12, 2023 from 10:30 AM to 11:10 AM PST
Jun 8, 2022 at 3:30 PM EDT